Germany rouses Eisai's fury with second Fycompa rejection

Eisai has said it is "outraged" by the latest German health technology assessment (HTA) decision, which found no evidence of additional benefit for epilepsy drug Fycompa (perampanel). IQWiG's verdict is a blow to the company, which has already been through the German system once before.